(Q34769926)

4 August 2017

1 reference

title

Spotlight on ziprasidone in schizophrenia and schizoaffective disorder (English)

1 reference

4 August 2017

1 reference

3

Gillian M Keating

1 reference

4 August 2017

Nishan S Gunasekara

1

1 reference

4 August 2017

Caroline M Spencer

series ordinal

2

1 reference

4 August 2017

language of work or name

1 reference

1 January 2002

1 reference

4 August 2017

1 reference

4 August 2017

16

1 reference

4 August 2017

645-652

1 reference

4 August 2017

9

1 reference

https://scigraph.springernature.com/pub.10.2165/00023210-200216090-00005

4 August 2017

0 references

cites work

Identification of the major human liver cytochrome P450 isoform(s) responsible for the formation of the primary metabolites of ziprasidone and prediction of possible drug interactions

1 reference

12 December 2020

Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death

1 reference

12 December 2020

The ratios of serotonin2 and dopamine2 affinities differentiate atypical and typical antipsychotic drugs

1 reference

12 December 2020

The time course of binding to striatal dopamine D2 receptors by the neuroleptic ziprasidone (CP-88,059-01) determined by positron emission tomography.

1 reference

12 December 2020

An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder

1 reference

12 December 2020

The Mechanism of Action of Novel Antipsychotic Drugs

1 reference

12 December 2020

Ziprasidone and the pharmacokinetics of a combined oral contraceptive

1 reference

12 December 2020

Typical and atypical antipsychotic occupancy of D2 and S2 receptors: an autoradiographic analysis in rat brain.

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in healthy volunteers treated with cimetidine or antacid

1 reference

12 December 2020

Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients

1 reference

12 December 2020

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

1 reference

12 December 2020

The effects of ziprasidone on steady-state lithium levels and renal clearance of lithium

1 reference

12 December 2020

Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial

1 reference

12 December 2020

Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity

1 reference

12 December 2020

The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers

1 reference

12 December 2020

Interaction of antipsychotic drugs with neurotransmitter receptor sites in vitro and in vivo in relation to pharmacological and clinical effects: role of 5HT2 receptors.

1 reference

12 December 2020

Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia

1 reference

12 December 2020

Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence

1 reference

12 December 2020

Ziprasidone: pharmacology, clinical progress and therapeutic promise

1 reference

12 December 2020

Dose dependent occupancy of central dopamine D2 receptors by the novel neuroleptic CP-88,059-01: a study using positron emission tomography and 11C-raclopride.

1 reference

12 December 2020

Ziprasidone and the activity of cytochrome P450 2D6 in healthy extensive metabolizers

1 reference

12 December 2020

The effect of timing of a standard meal on the pharmacokinetics and pharmacodynamics of the novel atypical antipsychotic agent ziprasidone.

1 reference

12 December 2020

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers

1 reference

12 December 2020

Single- and multiple-dose pharmacokinetics of ziprasidone in healthy young and elderly volunteers

1 reference

12 December 2020

Positron emission tomographic analysis of central 5-hydroxytryptamine2 receptor occupancy in healthy volunteers treated with the novel antipsychotic agent, ziprasidone.

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function

1 reference

12 December 2020

The effects of ketoconazole on ziprasidone pharmacokinetics--a placebo-controlled crossover study in healthy volunteers

1 reference

12 December 2020

The pharmacokinetics of ziprasidone in subjects with normal and impaired renal function

1 reference

12 December 2020

Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis. Ziprasidone I.M. Study Group.

1 reference

12 December 2020

10.2165/00023210-200216090-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

4 August 2017

0 references

1 reference